The role of post-remission chemotherapy for older patients with acute myelogenous leukemia

Leukemia and Lymphoma

Volumn 47, Issue 4, 2006, Pages 689-695

  Abou Jawde, Rony M ^a   Sobecks, Ronald ^a   Pohlman, Brad ^a   Rybicki, Lisa ^a   Advani, Anjali ^a   Sekeres, Mikkael ^a   Kalaycio, Matt ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

AML; Induction chemotherapy; Older; Post remission chemotherapy

Indexed keywords

CYTARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; FEMALE; HUMAN; HUMAN TISSUE; KARYOTYPE; LEUKEMIA REMISSION; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT CONTRAINDICATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW CELLS; CYTARABINE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33646784711     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500353554     Document Type: Article

References (39)

1. Ferrara, F and Mirto, S and Zagonel, V and Pinto, A. (1998) Acute myeloid leukemia in the elderly: A critical review of therapeutic approaches and appraisal of results of therapy Leuk Lymp-homa, 29, pp. 375-382.
2. Stone, R. (2002) The difficult problem of acute myeloid leukemia in the older adult CA Cancer J Clin, 52, pp. 363-371.
3. Estey, E. (2000) How I treat older patients with AML Blood, 96, pp. 1670-1673.
4. Sekeres, M and Stone, R. (2002) Older adults with acute myeloid leukemia Curr Oncol Rep, 4, pp. 403-409.
5. Lowenberg, B and Zittoun, R and Kerkhofs, H and Jehn, U and Abels, J and Debusscher, L et al. (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group J Clin Oncol, 7, pp. 1268-1274.
6. Stone, R and Mayer, R. (1993) The approach to the elderly patient with acute myeloid leukemia Hematol Oncol Clin North Am, 7, pp. 65-79.
7. Feldman, E. (1995) Acute myelogenous leukemia in the older patient Semin Oncol, 22(Suppl 1), pp. 21-24.
8. Rees, J and Gray, R and Swirsky, D and Hayhoe, F. (1986) Principal results of the Medical Research Council's Eighth acute myeloid leukaemia trial Lancet, 2, pp. 1236-1241.
9. Liu Yin, J and Johnson, P and Davies, J and Flanagan, N and Gorst, D and Lewis, M. (1991) Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia Br J Haematol, 79, pp. 415-420.
10. Lowenberg, B and Suciu, S and Archimbaud, E and Haak, H and Stryckmans, P and de Cataldo, R et al. (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group J Clin Oncol, 16, pp. 872-881.
11. Rowe, J and Neuberg, D and Friedenberg, W and Bennett, J and Paietta, E and Makary, A et al. (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group Blood, 103, pp. 479-485.
12. Stone, R and Berg, D and George, S and Dodge, R and Paciucci, P and Schulman, P et al. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia Cancer and Leukemia Group B. N Engl J Med, 332, pp. 1671-1677.
13. Rowe, J and Andersen, J and Mazza, J and Bennett, J and Paietta, E and Hayes, F et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 - 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490) Blood, 86, pp. 457-462.
14. Lowenberg, B and Suciu, S and Archimbaud, E and Ossenkoppele, G and Verhoef, G and Vellenga, E et al. (1997) Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group Blood, 90, pp. 2952-2961.
15. Godwin, J and Kopecky, K and Head, D and Willman, C and Leith, C and Hynes, H et al. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest oncology group study (9031) Blood, 91, pp. 3607-3615.
16. List, A and Kopecky, K and Willman, C and Head, D and Persons, D and Slovak, M et al. (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study Blood, 98, pp. 3212-3220.
17. Lancet, J and Willman, C and Bennett, J. (2000) Acute myelogenous leukemia and aging. Clinical interactions Hematol Oncol Clin North Am, 14, pp. 251-267.
18. Pinto, A and Zagonel, V and Ferrara, F. (2001) Acute myeloid leukemia in the elderly: Biology and therapeutic strategies Crit Rev Oncol Hematol, 39, pp. 275-287.
19. Mayer, R and Davis, R and Schiffer, C and Berg, D and Powell, B and Schulman, P and (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med, 331, pp. 896-903.
20. Hamblin, T. (1995) Disappointments in treating acute leukemia in the elderly N Engl J Med, 332, pp. 1712-1713.
21. Bennett, J and Catovsky, D and Daniel, M and Flandrin, G and Galton, D and Gralnick, H and (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group Ann Intern Med, 103, pp. 620-635.
22. Kalaycio, M. (1997) Inpatient management of acute leukemia Cleve Clin J Med, 64, pp. 385-389.
23. Cheson, B and Cassileth, P and Head, D and Schiffer, C and Bennett, J and Bloomfield, C et al. (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia J Clin Oncol, 8, pp. 813-819.
24. Kalaycio, M and Pohlman, B and Elson, P and Lichtin, A and Hussein, M and Tripp, B et al. (2001) Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor Am J Clin Oncol, 24, pp. 58-63.
25. Lee, S and Rosner, F. (1969) Treatment of AGL Arch Intern Med, 123, pp. 205-206.
26. Boggs, D and Wintrobe, M and Cartwright, G. (1969) To treat or not to treat acute granulocytic leukemia. II Arch Intern Med, 123, pp. 568-570.
27. Rosner, F and Sawitsky, A and Grunwald, H and Kanti, R. (1976) Letter: acute granulocytic leukemia in the elderly Arch Intern Med, 136, pp. 120.
28. Stone, R and Berg, D and George, S and Dodge, R and Paciucci, P and Schulman, P et al. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine Blood, 98, pp. 548-553.
29. Feldman, E and Seiter, K and Damon, L and Linker, C and Rugo, H and Ries, C et al. (1997) A randomized trial of high- versus standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia Leukemia, 11, pp. 485-489.
30. Ferrara, F and Mirto, S. (1996) Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly Br J Haematol, 92, pp. 627-631.
31. Nannya, Y and Kanda, Y and Oshima, K and Kaneko, M and Yamamoto, R and Chizuka, A et al. (2002) Prognostic factors in elderly patients with acute myelogenous leukemia: A single center study in Japan Leuk Lymphoma, 43, pp. 83-87.
32. Lowenberg, B and Downing, J and Burnett, A. (1999) Acute myeloid leukemia N Engl J Med, 341, pp. 1051-1062.
33. Walters, R and Kantarjian, H and Keating, M and Estey, E and McCredie, K and Freireich, E. (1987) Intensive treatment of acute leukemia in adults 70 years of age and older Cancer, 60, pp. 149-155.
34. Frohling, S and Schlenk, R and Stolze, I and Bihlmayr, J and Benner, A and Kreitmeier, S et al. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations J Clin Oncol, 22, pp. 624-633.
35. Kottaridis, P and Gale, R and Linch, D. (2003) Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia Leuk Lymphoma, 44, pp. 905-913.
36. Gajewski, J and Ho, W and Nimer, S and Hirji, K and Gekelman, L and Jacobs, A et al. (1989) Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome J Clin Oncol, 7, pp. 1637-1645.
37. Leith, C and Kopecky, K and Godwin, J and McConnell, T and Slovak, M and Chen, I et al. (1997) Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood, 89, pp. 3323-3329.
38. Grimwade, D and Walker, H and Harrison, G and Oliver, F and Chatters, S and Harrison, C et al. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood, 98, pp. 1312-1320.
39. Hiddemann, W and Kern, W and Schoch, C and Fonatsch, C and Heinecke, A and Wormann, B et al. (1999) Management of acute myeloid leukemia in elderly patients J Clin Oncol, 17, pp. 3569-3576.